THERIVA BIOLOGICS INC (TOVX)
NYSE MKTHealth CareBiotechnologySnapshot 2026-09-04
$0.250.00%
Close 2026-09-04 · 1-day change
NYSE MKTHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TOVX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Conduct VIRAGE2 Phase 2a trial to evaluate more frequent repeated dosing of VCN-01 with chemotherapy in metastatic pancreatic ductal adenocarcinoma patients.
Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2 and a July 2026 regulatory update. The VIRAGE2 Phase 2a trial is underway to evaluate more frequent repeated dosing of VCN-01 in metastatic PDAC, expected to enroll 6 patients and complete enrollment in H2 2026 with initial data by Q3 2027. This aligns with management's stated goal to refine dosing for a future pivotal Phase 3 trial, showing delivering progress on clinical development.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Dosing of the first patients in the VIRAGE2 trial brings us closer to refining a VCN-01 dosing regimen for potential Phase 3 trial in metastatic PDAC.”
“We plan to generate feasibility data by conducting a small study administering more frequent VCN-01 doses for a longer period in metastatic PDAC patients.”
Design and initiate Phase 2/3 clinical trial of intravitreal VCN-01 plus topotecan for retinoblastoma with vitreous seeds refractory to current chemotherapy.
Stated in 2 quarters including 2026-Q1 and 2026-Q2. Management completed the design of a Phase 2/3 trial for VCN-01 plus topotecan in retinoblastoma and treated two compassionate use patients. The protocol is planned for FDA discussion in Q3 2026. This shows ongoing development progress consistent with management's stated plans.
“Completed design of proposed Phase 2/3 clinical trial of intravitreal VCN-01 with topotecan in children with refractory retinoblastoma.”
“Made VCN-01 available for compassionate use in retinoblastoma; two patients treated with intravitreal VCN-01 plus topotecan.”
Further clinical development of VCN-01 with immune checkpoint inhibitors in refractory or metastatic head and neck squamous cell carcinoma (HNSCC).
Newly stated in 2026-Q2 via a press release reporting Phase 1 clinical trial results in refractory head and neck cancer showing prolonged overall survival with VCN-01 plus durvalumab. Median overall survival ranged from 10.3 to 17.3 months across arms. This supports management's stated intent to advance clinical development in this indication.
Control operating expenses and preserve cash to fund operations into early 2027 amid ongoing clinical development.
Stated in 2 quarters, 2026-Q1 and 2026-Q2, management reported cash declining from $14.4M to $11.3M with runway into Q1 2027. Net losses increased from $2.0M to $3.2M over these quarters. Operating expenses remain significant but cash runway is consistent with management's stated funding horizon, indicating limited progress in reducing burn but maintaining runway.
“Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027.”
“Cash and cash equivalents totaled $14.4 million as of March 31, 2026; cash runway into Q1 2027.”
Leverage license agreement with Rasayana Therapeutics for exclusive worldwide rights to develop and commercialize certain products.
Newly stated in 2026-Q1. Management disclosed a license agreement with Rasayana Therapeutics granting exclusive worldwide rights to develop and commercialize products. No subsequent updates or financial impact reported, indicating initial announcement without further delivery evidence.
“Entered into license agreement with Rasayana Therapeutics granting exclusive worldwide license to develop and commercialize products.”
Over the trailing year it converted 1.09x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
18 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.